U.S. Markets closed

Becton, Dickinson (BDX) Beats on Q4 Earnings & Revenues

Zacks Equity Research

Becton, Dickinson and Company BDX, popularly known as BD, reported fourth-quarter fiscal 2016 earnings of $2.12 per share, which beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter.

At comparable currency-neutral basis, revenues climbed 5.6% to $3.23 billion, marginally better than the Zacks Consensus Estimate of $3.22 billion.


Quarter Details


BD Medical revenues grew 7.9% year over year to almost $2.24 billion. The upside came from strong performance by Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units. Results were driven by double-digit growth in China, strength in dispensing and infusion, and sales of safety-engineered products.

BD Lifesciences revenues increased 2.1% from the year-ago quarter to $996 million. The upside came from Diagnostic Systems, Biosciences, research instruments and reagents in the U.S. This was partially offset by declines in Africa.

Geographically, U.S. revenues increased 6.7% to roughly $1.75 billion, while International revenues were up 5.2% on a currency-neutral basis to $1.48 billion.


For fiscal 2017, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 4.5% to 5.0%.

Meanwhile, adjusted earnings (on a currency-neutral basis) are expected in the range of $9.62 to $9.72, reflecting year-over-year growth of 12.0% to 13.0%. However after including the estimated unfavorable impact from foreign currency, the company expects adjusted diluted earnings per share between $9.45 and $9.55, which represents growth of approximately 10.0% to 11.0%.


BECTON DICKINSO Price, Consensus and EPS Surprise

BECTON DICKINSO Price, Consensus and EPS Surprise | BECTON DICKINSO Quote

Zacks Rank & Key Picks


Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the same space are Intuitive Surgical Inc. ISRG, AngioDynamics Inc. ANGO and C.R. Bard BCR.

Notably, Intuitive Surgical and AngioDynamics sport a Zacks Rank #1 (Strong Buy), while C.R. Bard has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 32.9%.

AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 23.14%.

C.R. Bard recorded a stellar one-year return of almost 15.02%. Notably, the company has an impressive long-term expected growth rate of 11.16%.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research